Last edition
News about "Biocon"
Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions
This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.
Biocon | 18/09/2025 | By Dineshwori
Biocon Opens First US Manufacturing Facility in New Jersey
The Cranbury facility will help Biocon diversify its manufacturing base, strengthen its supply chain
and accelerate the expansion of its global footprint.
Biocon | 11/09/2025 | By Dineshwori
Biocon Biologics Secures FDA Approval for Kirsty
Biocon Biologics has announced that it has received FDA approval for KIRSTY (Insulin Aspart-xjhz), making it the first and only interchangeable biosimilar to NovoLog in the US, marking a major milestone in expanding affordable insulin options.
Biocon | 16/07/2025 | By Mrinmoy Dey
Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health
Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.
Biocon | 03/07/2025 | By Mrinmoy Dey | 123
Biocon Join Hands with Tabuk Pharma to Commercialize its GLP -1 Products in Middle East
The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.
Biocon | 27/09/2024 | By Aishwarya | 483
Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok
Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.
Biocon | 28/05/2024 | By Aishwarya | 498
Biocon Signs Semi-Exclusive Distribution and Supply Deal for with Medix
Biocon Ltd. has signed a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda).
Biocon | 13/05/2024 | By Aishwarya | 180
Biocon Signs Exclusive Licensing and Supply Deal with Biomm for Drug Commercialization
Biocon Limited has signed an exclusive licensing and supply agreement with Biomm to commercialize its vertically integrated drug product, Semaglutide (gOzempic).
Biocon | 19/04/2024 | By Aishwarya | 311
EDQM conducts GMP inspection at Biocon's API site in Bengaluru
As per the filing, the inspection was held between September 12-14, 2022 and issued a list of deficiencies on October 5, 2022
Biocon | 10/10/2022 | By Sudeep Soparkar | 383
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy